Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A_2A antagonists/MAO‑B inhibitors

References

• C.J. Van der Schyf and W. Geldenhuys, Multimodal drugs and their future for Alzheimer’s and Parkinson’s disease, Int. Rev. Neurobiol. 100 (2011), pp. 107–125.
   PubMed Web of Science ®Google Scholar
• W.J. Geldenhuys, M.B. Youdim, R.T. Carroll, and C.J. Van der Schyf, The emergence of designed multiple ligands for neurodegenerative disorders, Prog. Neurobiol. 94 (2011), pp. 347–359.
   PubMed Web of Science ®Google Scholar
• L. Brichta, P. Greengard, and M. Flajolet, Advances in the pharmacological treatment of Parkinson's disease: Targeting neurotransmitter systems, Trends Neurosci. 36 (2013), pp. 543–554.
   PubMed Web of Science ®Google Scholar
• S. Patyar, A. Prakash, and B. Medhi, Dual inhibition: A novel promising pharmacological approach for different disease conditions, J. Pharm. Pharmacol. 63 (2011), pp. 459–471.
   PubMed Web of Science ®Google Scholar
• P.T. Francis and E.K. Perry, Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies, Mov. Disorders 22 (2007), pp. S351–S357.
   PubMed Web of Science ®Google Scholar
• A. Rampa, F. Belluti, S. Gobbi, and A. Bisi, Hybrid-based multi-target ligands for the treatment of Alzheimer's disease, Curr. Top. Med. Chem. 11 (2011), pp. 2716–2730.
   PubMed Web of Science ®Google Scholar
• M.A. Schwarzschild, L. Agnati, K. Fuxe, J.-F. Chen, and M. Morelli, Targeting adenosine A 2A receptors in Parkinson's disease, Trends Neurosci. 29 (2006), pp. 647–654.
   PubMed Web of Science ®Google Scholar
• N. Szabó, Z.T. Kincses, and L. Vécsei, Novel therapy in Parkinson's disease: Adenosine A2A receptor antagonists, Expert Opin. Drug Metab. Toxicol. 7 (2011), pp. 441–455.
   PubMed Web of Science ®Google Scholar
• A. Schapira, Present and future drug treatment for Parkinson’s disease, J. Neuro. Neurosur. PS. 76 (2005), pp. 1472–1478.
   PubMed Web of Science ®Google Scholar
• A. Lees, Alternatives to levodopa in the initial treatment of early Parkinson’s disease, Drug. Aging 22 (2005), pp. 731–740.
   PubMed Web of Science ®Google Scholar
• J.-F. Chen, S. Steyn, R. Staal, J.P. Petzer, K. Xu, C.J. Van der Schyf, K. Castagnoli, P.K. Sonsalla, N. Castagnoli, and M.A. Schwarzschild, 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism, J. Biol. Chem. 277 (2002), pp. 36040–36044.
   PubMed Web of Science ®Google Scholar
• N. Vlok, S.F. Malan, N. Castagnoli, J.J. Bergh, and J.P. Petzer, Inhibition of monoamine oxidase B by analogues of the adenosine A 2A receptor antagonist (E)-8-(3-chlorostyryl) caffeine (CSC), Bioorg. Med. Chem. 14 (2006), pp. 3512–3521.
   PubMed Web of Science ®Google Scholar
• D. van den Berg, K.R. Zoellner, M.O. Ogunrombi, S.F. Malan, G. Terre’Blanche, N. Castagnoli, J.J. Bergh, and J.P. Petzer, Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues, Bioorg. Med. Chem. 15 (2007), pp. 3692–3702.
   PubMed Web of Science ®Google Scholar
• S. Rivara, G. Piersanti, F. Bartoccini, G. Diamantini, D. Pala, T. Riccioni, M.A. Stasi, W. Cabri, F. Borsini, and M. Mor, Synthesis of (E)-8-(3-chlorostyryl) caffeine analogues leading to 9-deazaxanthine derivatives as dual A2A antagonists/MAO-B inhibitors, J. Med. Chem. 56 (2013), pp. 1247–1261.
   PubMed Web of Science ®Google Scholar
• A. Stößel, M. Schlenk, S. Hinz, P. Küppers, J. Heer, M. Gütschow, and C.E. Müller, Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4 H-3, 1-benzothiazin-4-ones, J. Med. Chem. 56 (2013), pp. 4580–4596.
   PubMed Web of Science ®Google Scholar
• S. Chavan, S. Bhayye, and M.E. Sobhia, Molecular dynamics directed CoMFA studies on carbocyclic neuraminidase inhibitors, Mol. Divers 15 (2011), pp. 979–987.
   PubMed Web of Science ®Google Scholar
• LigPrep 3.4, Schrödinger, LLC, New York, NY, 2015.
   Google Scholar
• D. Shivakumar, J. Williams, Y. Wu, W. Damm, J. Shelley, and W. Sherman, Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field, J. Chem. Theory Comput. 6 (2010), pp. 1509–1519.
   PubMed Web of Science ®Google Scholar
• S.L. Dixon, A.M. Smondyrev, E.H. Knoll, S.N. Rao, D.E. Shaw, and R.A. Friesner, PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results, J. Comput. Aid. Mol. Des. 20 (2006), pp. 647–671.
   PubMed Web of Science ®Google Scholar
• S.L. Dixon, A.M. Smondyrev, and S.N. Rao, PHASE: A novel approach to pharmacophore modeling and 3D database searching, Chem. Biol. Drug. Des. 67 (2006), pp. 370–372.
   PubMed Web of Science ®Google Scholar
• M.K. Teli and G. Rajanikant, Pharmacophore generation and atom-based 3D-QSAR of N-iso-propyl pyrrole-based derivatives as HMG-CoA reductase inhibitors, Org. Med. Chem. Lett. 2 (2012), pp. 1–10.
   PubMedGoogle Scholar
• K.K. Reddy, S.K. Singh, N. Dessalew, S.K. Tripathi, and C. Selvaraj, Pharmacophore modelling and atom-based 3D-QSAR studies on N-methyl pyrimidones as HIV-1 integrase inhibitors, J. Enzyme Inhib. Med. Chem. 27 (2012), pp. 339–347.
   PubMed Web of Science ®Google Scholar
• T. Mehmood, K.H. Liland, L. Snipen, and S. Sæbø, A review of variable selection methods in partial least squares regression, Chemometr. Intell. Lab. Syst. 118 (2012), pp. 62–69.
   Web of Science ®Google Scholar
• G. Tóth, Z. Bodai, and K. Héberger, Estimation of influential points in any data set from coefficient of determination and its leave-one-out cross-validated counterpart, J. Comput. Aid. Mol. Des. 27 (2013), pp. 837–844.
   PubMed Web of Science ®Google Scholar
• Sybyl 7.2, Triops Inc, St.
   Google Scholar
• P.C. Nair, K. Srikanth, and M.E. Sobhia, QSAR studies on CCR2 antagonists with chiral sensitive hologram descriptors, Bioorg. Med. Chem. Lett. 18 (2008), pp. 1323–1330.
   PubMed Web of Science ®Google Scholar
• J. Verma, V.M. Khedkar, and E.C. Coutinho, 3D-QSAR in drug design-a review, Curr. Top. Med. Chem. 10 (2010), pp. 95–115.
   PubMed Web of Science ®Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q 2!, J. Mol. Graph. Model. 20 (2002), pp. 269–276.
   PubMed Web of Science ®Google Scholar
• K. Roy and I. Mitra, On the use of the metric rm 2 as an effective tool for validation of QSAR models in computational drug design and predictive toxicology, Mini Rev. Med. Chem. 12 (2012), pp. 491–504.
   PubMed Web of Science ®Google Scholar
• K. Roy, I. Mitra, S. Kar, P.K. Ojha, R.N. Das, and H. Kabir, Comparative studies on some metrics for external validation of QSPR models, J. Chem. Inf. Model. 52 (2012), pp. 396–408.
   PubMed Web of Science ®Google Scholar
• Maestro 10.2, Schrödinger, LLC, New York, NY, 2015.
   Google Scholar
• Canvas 2.4, Schrödinger, LLC, New York, NY, 2015.
   Google Scholar
• D. Stumpfe and J.R. Bajorath, Exploring activity cliffs in medicinal chemistry: Miniperspective, J. Med. Chem. 55 (2012), pp. 2932–2942.
   PubMed Web of Science ®Google Scholar
• C. Rupakheti, A.M. Virshup, W. Yang, and D.N. Beratan, A Strategy to Discover Diverse Optimal Molecules in the Small Molecule Universe, J. Chem. Inf, Model, 55, 2015 pp. 529–537.
   Google Scholar
• G. Lebon, T. Warne, P.C. Edwards, K. Bennett, C.J. Langmead, A.G. Leslie, and C.G. Tate, Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation, Nature 474 (2011), pp. 521–525.
   PubMed Web of Science ®Google Scholar
• D. Bonivento, E.M. Milczek, G.R. McDonald, C. Binda, A. Holt, D.E. Edmondson, and A. Mattevi, Potentiation of ligand binding through cooperative effects in monoamine oxidase B, J. Biol. Chem. 285 (2010), pp. 36849–36856.
   PubMed Web of Science ®Google Scholar
• Schrödinger Suite 2015, Protein Preparation Wizard; Epik 3.2, Schrödinger, LLC, New York, NY, 2015; Impact 6.7, Schrödinger, LLC, New York, NY, 2015; Prime 4.0, Schrödinger, LLC, New York, NY, 2015.
   Google Scholar
• Glide 6.7, Schrödinger, LLC, New York, NY, 2015.
   Google Scholar
• R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, and D.T. Mainz, Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, J. Med. Chem. 49 (2006), pp. 6177–6196.
   PubMed Web of Science ®Google Scholar
• Desmond Molecular Dynamics System 4.0, D. E. Shaw Research, New York, NY, 2014.
   Google Scholar
• A. Speck-Planche, V.V. Kleandrova, F. Luan, and M.N.D.S. Cordeiro, Rational drug design for anti-cancer chemotherapy: Multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents, Bioorg. Med. Chem. 20 (2012), pp. 4848–4855.
   PubMed Web of Science ®Google Scholar